# Batch-2 Escalation Packet — GLP-1 Neuropsychiatric RoB (19 user-supplied studies)

6 domain-cells where the two reviewers disagreed, reconciliation failed to converge, and the blinded Sonnet-5 judge declined to resolve on the verified evidence. Each entry gives both reviewers' candidate ratings, the reconciliation outcome, the judge's deciding signalling question + what evidence is missing, and the supporting quotes. Fill in 'Your call'.

**Adjudications received so far:** 41616750 D4→Serious · 41862258 D3→Moderate · 41862258 D6→Moderate. **Still pending:** 42380063 D3 · 31189511 D5 (REWIND) · 30291013 D5 (Harmony).

---

# ============ Observational (ROBINS-I) ============

## 41862258 - D3 (Bias in classification of interventions)

- **Reviewer 1 (claude:claude-opus-4-8)**: Low
- **Reviewer 2 (openai:gpt-5.6-sol)**: Moderate
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers cite identical verified quotes for all three signalling questions but diverge on 3.2 (Y vs PY), which drives the differing domain ratings (Low vs Moderate); the quoted text alone does not clarify whether classification was fully prospective/blinded to outcome, so the discrepancy cannot be resolved from the evidence given.

**Reviewer 1 rationale.** Interventions are clearly defined by ATC codes and constructed from prospectively recorded dispensing data via a validated method (PRE2DUP), free of outcome-driven misclassification. Reliance on dispensing rather than actual intake is a minor limitation the authors acknowledge as not a direct adherence measure.

Reviewer 1 signalling answers:
    - **3.1** `[Y]` [verbatim, ellipsis-joined]: "The exposures analysed were use of the most frequently prescribed GLP-1-receptor agonist (Anatomical Therapeutic Chemical [ATC] code A10BJ), namely semaglutide; liraglutide; exenatide; and dulaglutide."
    - **3.2** `[Y]` [verbatim]: "The PRE2DUP method15 was used to construct individual drug-use periods by modelling data from the Prescribed Drug Register."
    - **3.3** `[N]` [verbatim]: "The PRE2DUP method15 was used to construct individual drug-use periods by modelling data from the Prescribed Drug Register."

**Reviewer 2 rationale.** Drug groups were clearly defined and classified from prescription-register data before outcome analysis. Some exposure misclassification remains possible because use periods were modelled and were not direct measures of adherence.

Reviewer 2 signalling answers:
    - **3.1** `[Y]` [verbatim, ellipsis-joined]: "The exposures analysed were use of the most frequently prescribed GLP-1-receptor agonist (Anatomical Therapeutic Chemical [ATC] code A10BJ), namely semaglutide; liraglutide; exenatide; and dulaglutide."
    - **3.2** `[PY]` [verbatim]: "The PRE2DUP method15 was used to construct individual drug-use periods by modelling data from the Prescribed Drug Register."
    - **3.3** `[N]` [verbatim]: "The PRE2DUP method15 was used to construct individual drug-use periods by modelling data from the Prescribed Drug Register."

**Candidate ratings:** Low | Moderate
**Your call:** ____________   **Note:** ____________

---

## 41862258 - D6 (Bias in measurement of outcomes)

- **Reviewer 1 (claude:claude-opus-4-8)**: Low  ->(after reconciliation) Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: Moderate  ->(after reconciliation) Low
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> judge output unparseable (JSONDecodeError('Expecting property name enclosed in double quotes: line 1 column 356 (char 355)'))

**Reviewer 1 rationale.** Outcomes are objectively ascertained from national registers using identical coded definitions across exposed and unexposed periods within the same individual, so measurement is not differential by exposure. Detection of an outpatient contact during care could differ, but the outcome relies largely on hospitalisation/sick-leave/death events, limiting material bias.

Reviewer 1 signalling answers:
    - **6.1** `[N]` [verbatim]: "we defined this outcome as a composite of psychiatric hospital admissions (F00–F99), sick leave from work (either full-time or part-time sickness absence for more than 14 days due to psychiatric reasons [F00–F99]), hospitalisation due to self-harm (X60–X84 or Y10–Y34), and death due to suicide."
    - **6.2** `[N]` [verbatim]: "National Swedish electronic health registers were used to obtain and combine data through personal pseudonymised identification numbers."
    - **6.3** `[Y]` [verbatim]: "Hospitalisation and sick leave used codes for any psychiatric diagnosis to enable complete coverage for episodes of worsening mental health."
    - **6.4** `[N]` [verbatim]: "Within-individual design minimises selection bias and automatically eliminates the effects of time-invariant characteristics (gender, baseline severity of illness, or other comorbid conditions) by comparing specific treatment periods within the same individuals."

**Reviewer 2 rationale.** Self-harm was consistently defined using hospital-treated ICD-coded events across exposure periods, but events outside hospital care were not captured and assessor awareness was unreported. Differential measurement is not demonstrated, although some material under-ascertainment is possible.

Reviewer 2 signalling answers:
    - **6.1** `[PN]` [verbatim]: "An additional a priori-defined secondary outcome was self-harm (hospital-treated self-harm, X60–X84 or Y10–Y34)."
    - **6.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **6.3** `[Y]` [verbatim]: "The Swedish National Patient Register for inpatient and specialist outpatient visits, as well as the Microdata for Analysis of the Social Insurance (MiDAS) register containing data on sick leave (absence from work due to ill health) and disability pension diagnoses, were used to identify study participants."
    - **6.4** `[PN]` [verbatim]: "An additional a priori-defined secondary outcome was self-harm (hospital-treated self-harm, X60–X84 or Y10–Y34)."

**Candidate ratings:** Low | Moderate
**Your call:** ____________   **Note:** ____________

---

## 42380063 - D3 (Bias in classification of interventions)

- **Reviewer 1 (claude:claude-opus-4-8)**: Low
- **Reviewer 2 (openai:gpt-5.6-sol)**: Moderate
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers cite verified quotes but map them to different signalling questions (3.2 vs 3.3) with opposite conclusions, so it's unclear whether prescription-based classification introduces a time-varying/informative-censoring confound that would justify Moderate versus a clean Low rating. The underlying evidence is consistent with prospective, prescription-record-based classification, but the discrepancy in how reviewers structured 3.2/3.3 prevents confidently determining whether additional bias (e.g., differential misclassification or exclusion criteria) applies.

**Reviewer 1 rationale.** Interventions were clearly defined from prescription records fixed at the index date, with no scope for outcome-driven misclassification.

Reviewer 1 signalling answers:
    - **3.1** `[Y]` [verbatim]: "The GLP1RA group included dulaglutide, exenatide, lixisenatide, and liraglutide."
    - **3.2** `[Y]` [verbatim]: "initiation of therapy with a GLP1RA, SGLT2 inhibitors, or DPP4 inhibitors based on prescription records"
    - **3.3** `[N]` [verbatim]: "The index date was defined as the date of the first prescription for the drug of interest."

**Reviewer 2 rationale.** Drug groups were clearly defined before outcome occurrence, but exposure was based on prescriptions rather than confirmed dispensing or consumption. This permits some exposure misclassification, although it is not shown to be differential.

Reviewer 2 signalling answers:
    - **3.1** `[Y]` [verbatim]: "The GLP1RA group included dulaglutide, exenatide, lixisenatide, and liraglutide."
    - **3.2** `[Y]` [verbatim]: "The index date was defined as the date of the first prescription for the drug of interest."
    - **3.3** `[N]` [verbatim]: "Within each group, patients with prior exposure to other study drugs and a previous history of study outcomes were additionally excluded (e.g., prior DPP4 inhibitor use in the GLP1RA group)."

**Candidate ratings:** Low | Moderate
**Your call:** ____________   **Note:** ____________

---

## 41616750 - D4 (Bias due to deviations from intended interventions)

- **Reviewer 1 (claude:claude-opus-4-8)**: Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: Serious
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers rate most signalling questions NI with only partially overlapping verified quotes, and neither review's underlying signalling answers clearly justify their stated overall algo-independent rating (Serious vs Moderate) from the evidence alone. The verified quotes (routine variable follow-up, grouping of agents without dose/duration adjustment, lack of confounding adjustment) support concern but do not unambiguously discriminate between Moderate and Serious, so this should be escalated.

**Reviewer 1 rationale.** The study is essentially descriptive of usual-practice exposure with no data on adherence, dose, or co-interventions and no comparator to balance them. Given the descriptive (non-comparative) intent and silence on deviations, concern is Moderate.

Reviewer 1 signalling answers:
    - **4.1** `[NI]` [verbatim]: "Clinical follow-up occurred according to routine patterns within UHealth and varied depending on specialty involvement."
    - **4.2** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.3** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.4** `[NI]` [verbatim]: "We grouped multiple GLP-1 receptor agonists together and did not account for specific agent, dose, or exposure duration"
    - **4.5** `[NI]` [verbatim]: "We grouped multiple GLP-1 receptor agonists together and did not account for specific agent, dose, or exposure duration, which limits interpretability"
    - **4.6** `[N]` [verbatim]: "retrospective chart review did not permit adjustment for confounding variables"

**Reviewer 2 rationale.** Actual implementation, adherence, switching, and important psychiatric co-interventions were not adequately assessed. The analysis ignored specific agent, dose, and exposure duration despite an average of more than one agent per patient.

Reviewer 2 signalling answers:
    - **4.1** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.2** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.3** `[NI]` [verbatim]: "A structured data spreadsheet was created to extract demographic characteristics, including age, sex, race, ethnicity, and body mass index; GLP-1 treatment characteristics, such as agent name, start and end dates, duration of therapy, number of agents used, and percent weight loss; and psychiatric variables, including pre-existing and new-onset psychiatric diagnoses, dates of diagnosis, time from GLP-1 initiation to psychiatric presentation, psychiatric medication changes, and any documented personal or family psychiatric history when available."
    - **4.4** `[NI]` [verbatim]: "Eligible patients were 18 years or older, carried a diagnosis of T2DM or obesity, and had an active or historical prescription for semaglutide, tirzepatide, liraglutide, or dulaglutide within the study window."
    - **4.5** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.6** `[N]` [verbatim]: "We grouped multiple GLP-1 receptor agonists together and did not account for specific agent, dose, or exposure duration, which limits interpretability and prevents evaluation of agent-specific or dose-dependent effects."

**Candidate ratings:** Moderate | Serious
**Your call:** ____________   **Note:** ____________

---

---

# ============ RCT (RoB2) ============

## 31189511 - D5 (Bias in selection of the reported result)

- **Reviewer 1 (claude:claude-opus-4-8)**: High
- **Reviewer 2 (openai:gpt-5.6-sol)**: Some concerns
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers rely on the same 5.1 quote confirming a pre-specified protocol/SAP existed, which supports 'N' (low risk) for 5.1 rather than Reviewer A's 'NI', but 5.2 and 5.3 lack verified evidence establishing multiple analyses/measures were compared and selectively reported, which is needed to support Reviewer B's 'High' rating. Neither 'Some concerns' nor 'High' is fully supported by verified quotes, so the algorithmic RoB2 mapping cannot be confidently resolved without human review.

**Reviewer 1 rationale.** The prespecified outcomes and adverse events of special interest do not include any neuropsychiatric outcome; a result for the assessed outcome is absent from the report, so any such result would be non-prespecified/selectively reported.

Reviewer 1 signalling answers:
    - **5.1** `[N]` [verbatim]: "described in the protocol and prespecified statistical analysis plan (appendix pp 42–319)"
    - **5.2** `[NI]` [verbatim]: "Prespecified and all other adverse events were reported by investigators on case report forms."
    - **5.3** `[NI]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** The trial had a prespecified statistical analysis plan, but the provided text does not show that the specific neuropsychiatric outcome or analysis was prespecified. It also does not permit exclusion of selection among multiple measurements or analyses.

Reviewer 2 signalling answers:
    - **5.1** `[NI]` [verbatim]: "All efficacy and safety analyses were done according to an intention-to-treat approach that included all ran￾domly assigned participants irrespective of adherence, as described in the protocol and prespecified statistical analysis plan (appendix pp 42–319)."
    - **5.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.3** `[NI]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** High | Some concerns
**Your call:** ____________   **Note:** ____________

---

## 30291013 - D5 (Bias in selection of the reported result)

- **Reviewer 1 (claude:claude-opus-4-8)**: High
- **Reviewer 2 (openai:gpt-5.6-sol)**: Some concerns
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers cite the identical verified quote for 5.1 but assign different answers (N vs PN), with 5.2/5.3 unsupported by any verified text in either assessment, so the domain rating is underdetermined by the verified evidence alone.

**Reviewer 1 rationale.** The neuropsychiatric outcome was not prespecified among the study's defined safety outcomes of special interest, so any reported neuropsychiatric result would be a non-prespecified/post-hoc selection subject to selective reporting.

Reviewer 1 signalling answers:
    - **5.1** `[N]` [verbatim]: "The safety outcomes were the change in blood pressure and heart rate, change in eGFR, and adverse events of special interest, which included the development of prespecified malignancies (medullary thyroid cancer, pancreatic cancer, and haematological malignancies), pancreatitis, severe hypoglycaemia, injection site reac­tions, immunological reactions, diabetic retinopathy, worsening renal function, and death from any cause."
    - **5.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.3** `[NI]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** The reported prespecified outcomes do not include neuropsychiatric outcomes, and no prespecified analysis plan for such a result is documented. There is insufficient evidence to determine whether selection among multiple measurements or analyses was based on the results.

Reviewer 2 signalling answers:
    - **5.1** `[PN]` [verbatim]: "The safety outcomes were the change in blood pressure and heart rate, change in eGFR, and adverse events of special interest, which included the development of prespecified malignancies (medullary thyroid cancer, pancreatic cancer, and haematological malignancies), pancreatitis, severe hypoglycaemia, injection site reactions, immunological reactions, diabetic retinopathy, worsening renal function, and death from any cause."
    - **5.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.3** `[NI]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** High | Some concerns
**Your call:** ____________   **Note:** ____________

---


---

## Additional human-review items: algorithm-inconsistent domains

Per the skill traceability contract, any domain where `algo_consistent is False` also enters the human queue. These are NOT ESCALATE_TO_HUMAN but the reviewer's stated rating diverged from the deterministic RoB2 decision-table recompute.


### Kelly 2020 (32233338) — D3
- Reviewer ratings: R1=Some concerns (algo_consistent=False), R2=Some concerns (algo_consistent=None)
- Reason in queue: reviewer's stated D3 rating does not match the deterministic Table-10 recompute from its own signalling answers.
  - R1 3.1=Y (verified=True) | stated=Some concerns algo=Low
  - R1 3.2=NA (verified=None) | stated=Some concerns algo=Low
  - R1 3.3=NA (verified=None) | stated=Some concerns algo=Low
  - R1 3.4=NA (verified=None) | stated=Some concerns algo=Low
- **Your call:** ______________

### 42070571 (42070571) — D3
- Reviewer ratings: R1=Some concerns (algo_consistent=False), R2=Some concerns (algo_consistent=True)
- Reason in queue: reviewer's stated D3 rating does not match the deterministic Table-10 recompute from its own signalling answers.
  - R1 3.1=PN (verified=True) | stated=Some concerns algo=High
  - R1 3.2=PN (verified=True) | stated=Some concerns algo=High
  - R1 3.3=Y (verified=True) | stated=Some concerns algo=High
  - R1 3.4=NI (verified=True) | stated=Some concerns algo=High
- **Your call:** ______________